![5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮结构式](https://www.chemsrc.com/caspic/041/138154-39-9.png)
5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮结构式
|
常用名 | 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮 | 英文名 | C-1311 |
|---|---|---|---|---|
| CAS号 | 138154-39-9 | 分子量 | 350.41400 | |
| 密度 | 1.32g/cm3 | 沸点 | 605.8ºC at 760mmHg | |
| 分子式 | C20H22N4O2 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 320.2ºC | |
| 符号 |
GHS07 |
信号词 | Warning |
用途Symadex, also known as imidazoacridone; XLS-002 and C-1311, is a member of the novel imidazoacridinone family of anticancer agents. Imidazoacridone has shown activity in experimental tumour models both in vitro and in nude mice. C-1311 at the EC(99) dose delayed progression of cells through the S phase which was followed by G2 arrest. C-1311 does not induce rapid apoptosis in HT-29 cells, instead drug exposure leads to prolonged G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe. |
| 中文名 | 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮 |
|---|---|
| 英文名 | 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one |
| 英文别名 | 更多 |
| 密度 | 1.32g/cm3 |
|---|---|
| 沸点 | 605.8ºC at 760mmHg |
| 分子式 | C20H22N4O2 |
| 分子量 | 350.41400 |
| 闪点 | 320.2ºC |
| 精确质量 | 350.17400 |
| PSA | 69.87000 |
| LogP | 2.97100 |
| 蒸汽压 | 2.86E-15mmHg at 25°C |
| 折射率 | 1.68 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献：Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献：Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献：Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献：Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献：Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
DNA-damaging imidazoacridinone C-1311 induces autophagy followed by irreversible growth arrest and senescence in human lung cancer cells.
J. Pharmacol. Exp. Ther. 346(3) , 393-405, (2013) Imidazoacridinone 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. In this study, we describe the uni... |
|
|
Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.
Drug Metab. Dispos. 41(2) , 414-21, (2013) The acridinone derivates 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) are promising antitumor agents with high activ... |
|
|
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
J. Pharm. Biomed. Anal. 39(1-2) , 46-53, (2005) C1311 (5-[[2-(diethylamino)ethyl]amino]-8-hydroxyimidazo [4,5,1-de]-acridin-6-one-dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a novel group of rationally des... |
| 5-[[(diethylamino)ethyl]amino]-8-hydroxyimidazo[4,5,1-de]-acridine-6-one |
| C 1311 |
| XLS-002 |
| 6H-Imidazo(4,5,1-de)acridin-6-one,5-((2-(diethylamino)ethyl)amino)-8-hydroxy |
| 5-((2-(Diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo(4,5,1-de)acridin-6-one |
查看所有供应商和价格请点击：
